The role of postoperative PET-CT in the evaluation of patients with high-risk stage III colorectal cancer (CRC).

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 566-566
Author(s):  
O. Purim ◽  
Y. Asman ◽  
S. Bard ◽  
Y. Kundel ◽  
N. Wasserberg ◽  
...  
Keyword(s):  
High Risk ◽  
Lymph Nodes ◽  
Systemic Disease ◽  
Treatment Protocol ◽  
Retrospective Chart Review ◽  
Clinicopathological Characteristics ◽  
Stage Iii ◽  
Pet Ct ◽  
Ca 19.9

566 Background: Routine PET-CT evaluation is still not indicated for stage III CRC patients; however accumulating data suggest that it may modify these patients' staging and treatment. We hence evaluated the role of PET-CT in high risk stage III CRC patients and to characterize positive predictors. Methods: Retrospective chart review of stage III CRC patients who underwent PET-CT for being at high risk for systemic disease attributable to: early T stage (T < 3), grade > 3, < 12 lymph-nodes examined, > 3 involved lymph-nodes, elevated postoperative CEA and/or CA-19.9. The demographic and clinicopathological characteristics of patients found to have metastatic disease were compared to those who were negative. Results: Seventy-three patients (33 males [45%], median age 67 years [range: 29-88 years]) were included. Pathologic FDG-uptake was observed in 33 (45%) patients. Of them, 16 (22%) were upstaged with altered treatment protocol, 13 (18%) required further work-up and 4 (5%) were found to have post operative changes. Elevated post-operative CEA and CA-19.9 levels correlated with positive PET-CT (p = 0.002 and p = 0.015, respectively). None of the other examined parameters differed between the groups. With a median follow-up of 26 months (range:1-63 months), overall survival was 88% in patients with positive PET-CT and 92% in patients with negative PET-CT. Eight patients in the positive group were disease free following metastectomy, five were alive with disease, two patients died of disease and one patient died of other cause. Conclusions: Selective postoperative PET-CT influenced staging/therapy in 22% of high risk stage III CRC patients. Postoperative CEA and CA-19.9 levels may play a role in selecting eligible patients. Failure to identify other parameters may be related to the preexisting selection bias and the small cohort. No significant financial relationships to disclose.

The role of early postoperative PET-CT in patients with pathological stage III colon cancer: Results from a large single institution study.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 562-562
Author(s):  
Assaf Moore ◽  
Irit Ben-Aharon ◽  
Ofer Purim ◽  
Gali Perl ◽  
Olga Ulitsky ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Nodes ◽  
Metastatic Disease ◽  
Stage Iii ◽  
Individual Risk ◽  
Pathological Stage ◽  
Stage Iii Colon Cancer ◽  
Pet Ct

562 Background: Current staging of patients (pts) with pathological stage III colon cancer is suboptimal; many pts still recur despite unremarkable preoperative staging work-up. We previously reported that early postoperative PET-CT can alter the stage and management of pts with high risk stage III colon cancer in up to 19% of patients. The aim of the current study was to expand the previous one to a larger cohort and to determine the role of early postoperative PET-CT in the general population of stage III colon cancer pts, regardless of their individual risk. Methods: A retrospective chart review of all consecutive pts with stage III colon cancer who underwent early postoperative PET-CT between 2007 and 2016. Demographic and clinicopathological data were collected. Results: 247 pts, 124 (50%) males, with a median age of 66 years (range, 30-92), were included. Pathological stage was IIIA, IIIB and IIIC in 18 (7.3%), 161 (65.1%) and 72 (29.1%) pts, respectively. The median number of lymph nodes retrieved was 15 (range, 6-64) and that of positive lymph nodes was 2 (range, 0-21). High FDG-uptake was observed in 52 (21.0%) pts, including 6 (2.4%) who had clear postoperative changes, 10 (4.0%) who had a false positive abnormal uptake of whom 6 underwent invasive diagnostic procedures. The PET-CT results modified the management of 36 pts (14.5%) who were found to have true positive findings: 30 (12.1%) were proven to have overt metastatic disease and in 6 (2.4%) a second primary was discovered. With the median follow-up of 39.0 months (range 7.2-98.4 months), of the 30 pts found to be metastatic, 10 (33.3%) underwent curative treatments and are currently with no evidence of disease (NED). Updated data, on more patients and a longer follow-up, will be presented at the meeting. Conclusions: Early postoperative PET-CT changed the staging and treatment of 14.5% of resected stage III pts, and has the potential for early detection of curable metastatic disease. We currently evaluate this strategy and its actual impact in a prospective trial.

The role of postoperative PET-CT in the evaluation of patients with high-risk stage III colon cancer (CC).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14089-e14089
Author(s):  
Y. Kundel ◽  
B. Brenner ◽  
Y. Asman ◽  
N. Vaserberg
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Pet Ct

scholarly journals The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1575
Author(s):  
Lucia Zanoni ◽  
Riccardo Mei ◽  
Lorenzo Bianchi ◽  
Francesca Giunchi ◽  
Lorenzo Maltoni ◽  
...  
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Malignant Lesion ◽  
Lesion Detection ◽  
Histopathological Analysis ◽  
Choline Pet ◽  
Primary Prostate Cancer ◽  
Pet Ct

The primary aim of the study was to evaluate the role of [18F]Fluciclovine PET/CT in the characterization of intra-prostatic lesions in high-risk primary PCa patients eligible for radical prostatectomy, in comparison with conventional [11C]Choline PET/CT and validated by prostatectomy pathologic examination. Secondary aims were to determine the performance of PET semi-quantitative parameters (SUVmax; target-to-background ratios [TBRs], using abdominal aorta, bone marrow and liver as backgrounds) for malignant lesion detection (and best cut-off values) and to search predictive factors of malignancy. A six sextants prostate template was created and used by PET readers and pathologists for data comparison and validation. PET visual and semi-quantitative analyses were performed: for instance, patient-based, blinded to histopathology; subsequently lesion-based, un-blinded, according to the pathology reference template. Among 19 patients included (mean age 63 years, 89% high and 11% very-high-risk, mean PSA 9.15 ng/mL), 45 malignant and 31 benign lesions were found and 19 healthy areas were selected (n = 95). For both tracers, the location of the “blinded” prostate SUVmax matched with the lobe of the lesion with the highest pGS in 17/19 cases (89%). There was direct correlation between [18F]Fluciclovine uptake values and pISUP. Overall, lesion-based (n = 95), the performance of PET semiquantitative parameters, with either [18F]Fluciclovine or [11C]Choline, in detecting either malignant/ISUP2-5/ISUP4-5 PCa lesions, was moderate and similar (AUCs ≥ 0.70) but still inadequate (AUCs ≤ 0.81) as a standalone staging procedure. A [18F]Fluciclovine TBR-L3 ≥ 1.5 would depict a clinical significant lesion with a sensitivity and specificity of 85% and 68% respectively; whereas a SUVmax cut-off value of 4 would be able to identify a ISUP 4-5 lesion in all cases (sensitivity 100%), although with low specificity (52%). TBRs (especially with threshold significantly higher than aorta and slightly higher than bone marrow), may be complementary to implement malignancy targeting.

Detection of Lymph Node Metastases in Patients With Prostate Cancer: Comparing Conventional and Digital [18F]-fluorocholine PET-CT Using Histopathology as Reference

2021 ◽  
Author(s):  
Mimmi Bjöersdorff ◽  
Christopher Puterman ◽  
Jenny Oddstig ◽  
Jennifer Amidi ◽  
Sophia Zackrisson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Lymph Nodes ◽  
Lymph Node Metastases ◽  
Reconstruction Algorithms ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer ◽  
Node Metastases

Abstract Background: Positron emission tomography-computed tomography (PET-CT) can be used to detect and stage metastatic lymph nodes in intermediate to high-risk prostate cancer. Improvements to hardware, such as digital technology, and to software, such as reconstruction algorithms, have recently been made. We compared the capability of detecting regional lymph node metastases using conventional and digital silicon photomultiplier (SiPM)-based PET-CT technology for [18F]-fluorocholine (FCH). Extended pelvic lymph node dissection (ePLND) histopathology was used as the reference method.Methods: Retrospectively, a consecutive series of patients with prostate cancer who had undergone staging with FCH PET-CT before ePLND were included. Images were obtained with either a conventional or a SiPM-based PET-CT and compared. FCH uptake in pelvic lymph nodes beyond the uptake in the mediastinal blood pool was considered to be abnormal.Results: One hundred eighty patients with intermediate or high-risk prostate cancer were examined using a conventional Philips Gemini PET-CT (n = 93) between 2015 and 2017 or a digital GE Discovery MI PET-CT (n = 87) from 2017 to 2018. Images that were obtained using the Philips Gemini PET-CT system showed 19 patients (20%) with suspected lymph node metastases compared with 40 patients (46%) using the GE Discovery MI PET-CT. Sensitivity, specificity, and positive and negative predictive value (PPV and NPV) were 0.30, 0.84, 0.47, and 0.72, respectively, for the Philips Gemini and 0.60, 0.58, 0.30, and 0.83, respectively for GE Discovery MI. Area under the curve (AUC) in a receiver operating characteristics (ROC) analysis was similar between the two PET-CT systems (0.58 and 0.58, P = 0.8).Conclusions: A marked difference in sensitivity and specificity was found for the different PET-CT systems, although similar overall diagnostic performance. This is probably due to differences in both hard- and software, including reconstruction algorithms, and should be considered when new technology is introduced.

Role of High-Resolution Ultrasound and PET/CT Imaging for Preoperative Characterization of Sentinel Lymph Nodes in Cutaneous Melanoma

2013 ◽  
Vol 39 (1) ◽  
pp. 30-36 ◽  
Author(s):  
Torsten Hinz ◽  
Harald Voth ◽  
Hojjat Ahmadzadehfar ◽  
Tobias Hoeller ◽  
Joerg Wenzel ◽  
...  
Keyword(s):  
High Resolution ◽  
Lymph Nodes ◽  
Cutaneous Melanoma ◽  
Sentinel Lymph Nodes ◽  
Ct Imaging ◽  
Pet Ct

The role of F-18 FDG PET/CT in differentiating benign from malignant pulmonary masses and accompanying lymph nodes

2018 ◽  
Vol 66 (2) ◽  
pp. 130-135
Author(s):  
Arzu Cengiz ◽  
Funda Aydın ◽  
Murat Sipahi ◽  
Levent Dertsiz ◽  
Gülay Özbilim ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pulmonary Masses

Role of FDG-PET/CT in diagnosis of aortitis caused by Takayasu arteritis and IgG4-related systemic disease

Heart ◽  
2013 ◽  
Vol 99 (24) ◽  
pp. 1876.2-1876
Author(s):  
Mohammed Shamim Rahman ◽  
Lisa J Anderson
Keyword(s):  
Takayasu Arteritis ◽  
Fdg Pet ◽  
Systemic Disease ◽  
Pet Ct ◽  
Fdg Pet Ct

High risk breast cancer: Prospective data about the role of FDG PET/CT in pre- and post-operative settings

2015 ◽  
Vol 41 (1) ◽  
pp. S14
Author(s):  
S. Michieletto ◽  
T. Saibene ◽  
L. Evangelista ◽  
F. Barbazza ◽  
R. Grigoletto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Fdg Pet ◽  
Prospective Data ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document